Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry eye disease.


Clinical Trial Description

The clinical hypothesis for this study is that iNexin™ demonstrates safety and tolerability in subjects with DED and can be evaluated for further safety and efficacy measures compared to vehicle. This is a Phase 1b single-center, randomized, double masked, vehicle controlled clinical study to assess the safety and exploratory efficacy of iNexin™ compared to vehicle in subjects with Dry Eye Disease. A total of 36 subjects, at least 18 years of age, with a subject-reported history of DED in both eyes and meeting all other study eligibility criteria will be randomized to receive treatment with iNexin™ or vehicle. An individual subject's participation time is expected to be approximately 24 days. 36 eligible subjects will be randomized in a 2:1 allocation for each of three concentrations of iNexin™ to Vehicle, to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). There will also be a 1-day post-final dose follow-up visit (Visit 5). During a 7-day study run-in period prior to randomization (from Visit 1 to the evening before Visit 2), all subjects will receive Vehicle eye drops (Vehicle) bilaterally at the same dosing frequency as iNexin™ (BID). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05031806
Study type Interventional
Source FirstString Research, Inc.
Contact Gautam S Ghatnekar, PhD
Phone 8433883276
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 14, 2021
Completion date November 11, 2021

See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT03688802 - Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study) Phase 2
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3
Completed NCT01636206 - Safety Study of Lifitegrast to Treat Dry Eye Phase 3
Recruiting NCT04633863 - Study on Safety and Performance of an Artificial Tear in Dry Eye Treatment in Subjects With Ocular Surface Inflammation N/A
Recruiting NCT04658238 - Ocular Microbiome and Immune System in Dry Eyes
Completed NCT02284516 - A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3) Phase 3
Active, not recruiting NCT03467490 - Self-care Management Program for Dry Eye Disease Patients Using the heiQ N/A
Not yet recruiting NCT02943382 - Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD) N/A
Completed NCT02554084 - Optical Coherence Tomography of Tear Film Dynamics In-Vivo N/A
Completed NCT00610480 - Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops N/A